The court’s dismissal order reflects a jointly negotiated exit: plaintiff’s claims dismissed with prejudice signals a final resolution binding on CIT, while the without-prejudice moot dismissal of Sleep Number’s counterclaims is procedurally standard — there was no live invalidity controversy to adjudicate once the underlying claims were resolved. The fee-neutrality clause (‘each party to bear its own fees and costs’) is consistent with a settlement rather than a unilateral capitulation, though the absence of any financial disclosure leaves the economic terms of any agreement entirely outside the public record.

If your product team is building or maintaining a mobile application that communicates with a connected device — smart-health monitors, IoT home devices, wearables, or any networked consumer product — these three CIT patents represent a credible FTO concern. No court has construed their claims or adjudicated their validity. The Sleep Number case closed without any substantive merits ruling, leaving the patents’ scope legally untested. R&D and product leaders should commission an FTO review before shipping new connectivity features, particularly those involving application-layer device communication or data exchange protocols.

PatSnap Eureka’s FTO Search Agent allows your team to map the claim language of US6574239B1, US8291010B2, and US8266296B2 against your product’s technical architecture in minutes. Eureka surfaces relevant prior art, identifies claim limitations that may not read on your implementation, and flags related NPE litigation activity — giving IP counsel and product teams the intelligence needed to make informed go/no-go decisions on feature development without waiting weeks for a manual FTO report.